Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk
European Journal of Clinical Pharmacology · 2025
DOI: 10.1007/s00228-025-03870-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2025. Verfasst von Juliana de Oliveira Costa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Room 209, Samuel…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council (NHMRC) Ideas Grant, NHMRC Emerging Leader Investigator Grant, Ramaciotti Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Purpose
We quantified variation in the uptake of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor analogues (GLP-1RA) across sociodemographic, behavioural and clinical characteristics of people with type 2 diabetes (T2D) at high cardiovascular risk.
Methods
We used the 45 and Up Study survey data (2018–2020) linked to dispensing and service claims for 10,171 people with T2D (56% male, median age of 72 years, median diabetes duration of 11 years). We calculated the prevalence of GLP-1RA and SGLT2i use within 1 year and used logistic regressions to assess associations with each participant characteristic.
Results
We found that 2270 (22.3%) people with T2D used SGLT2i and 679 (6.7%) used GLP-1RA. Use of these medicines was higher in people diagnosed with diabetes for a longer period, a high number of comorbidities and survey year, decreased in older people, and varied by sex. After adjusting for these factors, utilisation of these medicines was lower among people who consume alcohol (versus non-drinkers) and higher among those with overweight or obesity. SGLT2i use was also higher in people who were less physically active or had established cardiovascular disease and lower in people with anxiety or depression. GLP-1RA use was higher among people with poorer health and lower in people born outside Australia/New Zealand.
Conclusion
Prevalent use of SGLT2i and GLP-1RA was suboptimal and varied across clinical characteristics and behavioural risk factors. While some variation reflects complexities in prescribing for this older population, there remains opportunity for optimised prescribing within this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Room 209, Samuels Building (F25), Sydney, NSW, 2052, Australia. j.costa@unsw.edu.au.
- Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Room 209, Samuels Building (F25), Sydney, NSW, 2052, Australia.
- Department of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, NSW, Australia.
- Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, NSW, Australia.
- Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, NSW, Australia.
- School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, NSW, Australia.
Förderung
- National Health and Medical Research Council (NHMRC) Ideas Grant
- NHMRC Emerging Leader Investigator Grant
- Ramaciotti Foundation
- NHMRC Centre of Research Excellence in Medicines Intelligence
- National Heart Foundation of Australia
- University of New South Wales
Zitieren
APA
de Oliveira Costa, J., Lin, J., Milder, T. Y., Havard, A., Greenfield, J. R., Day, R. O., Neuen, B. L., Gibson, A. A., Morton, J. I., Sacre, J. W., Pearson, S. A., & Falster, M. O. (2025). Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-025-03870-2
Vancouver
de Oliveira Costa J, Lin J, Milder TY, Havard A, Greenfield JR, Day RO, et al. Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk. European Journal of Clinical Pharmacology. 2025. doi:10.1007/s00228-025-03870-2
BibTeX
@article{deOliveiraCosta2025,
author = {de Oliveira Costa, Juliana and Lin, Jialing and Milder, Tamara Y and Havard, Alys and Greenfield, Jerry R and Day, Richard O and Neuen, Brendon L and Gibson, Alice A and Morton, Jedidiah I and Sacre, Julian W and Pearson, Sallie-Anne and Falster, Michael O},
title = {Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk},
journal = {European Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1007/s00228-025-03870-2}
}
EUVIMED